<?xml version='1.0' encoding='utf-8'?>
<document id="30317768"><sentence text="[Consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C]." /><sentence text="Approved direct-acting antiviral agents (DAA ) in chronic hepatitis C were introduced" /><sentence text=" Metabolism and pharmacokinetics data of DAAs were analyzed" /><sentence text=" Comorbidity and concomitant medications of chronic hepatitis C (CHC) patients were extracted from Chinese Health Insurance database" /><sentence text=" Drug-drug interactions (DDIs) were calculated by integrated above data and confirmed by using Liverpool DDI website" /><sentence text=" Based on those data, experts propose consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C, including pre-treatment, on-treatment, and post-treatment" /><sentence text="" /><sentence text="总结了中国目前已上市和即将上市的丙型肝炎直接抗病毒药物（DAAs）和治疗方案，分析了DAA的代谢途径，以及慢性丙型肝炎患者常见的合并疾病和常用药物，归纳可能出现的药物相互作用（DDI）相关问题和解决方案，提出DDI的管理意见，包括，应用DAAs前管理，DAA应用中的监测以及DAAs治疗完成后的DDI管理。" /><sentence text="" /></document>